Willow
Biosciences (CSE: WLLW) (OTCQB: CANSF) on Thursday announced its
financial and operating results for the three and nine months ended September
30, 2019. Among other highlights, the company reported that it ended the
quarter with around $23.2 million of working capital and $24 million of cash on
hand. Willow’s unaudited condensed consolidated interim financial statements
and related management’s discussion and analysis are available at www.SEDAR.com or on the
company’s website. “Over the past few months, Willow has continued to advance
its business strategy and achieved several important milestones,” Willow
Biosciences president and chief executive officer Trevor Peters stated in the
news release. “We have made meaningful progress on advancing our yeast strain
performance and fully expect to meet our projected timing of scale-up
development in the first half of 2020. In addition, we have completed the
commissioning of our three labs and expanded our team of highly skilled
scientists, preparing us for future development. As the market for CBD
and other cannabinoids continues to develop, Willow is positioned as a leader
in delivering ultra-pure, pharmaceutical grade cannabinoids, at a highly
competitive cost for the consumer packaged goods and pharmaceutical
industries.”
To view the full press release, visit http://ibn.fm/m9cxi
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Calgary,
Alberta, that produces high purity, plant-derived compounds that provide
building blocks for the global pharmaceutical, health and wellness, and
consumer packaged goods industries. Willow’s current focus is in the production
of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders,
among other significant indications. Willow’s science team has a proven track
record of developing manufacturing technologies for high purity compounds in
pain and cancer treatments. Willow’s manufacturing process creates a
consistent, scalable and sustainable product that allows for the discovery and
development of new life changing drugs. For more information, visit the
company’s website at www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment